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Abstract
Problem: In the United States, acute viral hepatitis most frequently is caused by infection with any of three distinct 
viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), or hepatitis C virus (HCV). These unrelated viruses are 
transmitted through different routes and have different epidemiologic profiles. Safe and effective vaccines have been 
available for hepatitis B since 1981 and for hepatitis A since 1995. No vaccine exists against hepatitis C. HBV and HCV 
can persist as chronic infections and represent a leading cause of chronic liver disease and hepatocellular carcinoma in 
the United States.
Reporting Period Covered: Cases in 2007, the most recent year for which data are available, are compared with those 
from previous years.
Description of System: Cases of acute viral hepatitis are reported voluntarily to CDC by state and territorial health 
departments via CDC’s National Notifiable Disease Surveillance System (NNDSS). Reports are received electronically 
via CDC’s National Electronic Telecommunications System for Surveillance (NETSS).
Results: Acute hepatitis A incidence has declined 92%, from 12.0 cases per 100,000 population in 1995 to 1.0 case per 
100,000 population in 2007, the lowest rate ever recorded. Declines were greatest among children and in those states 
where routine vaccination of children was recommended beginning in 1999. Acute hepatitis B incidence has declined 
82%, from 8.5 cases per 100,000 population in 1990 to 1.5 cases per 100,000 population in 2007, the lowest rate ever 
recorded. Declines occurred among all age groups but were greatest among children aged <15 years. Following a peak in 
1992, incidence of acute hepatitis C declined; however, since 2003, rates have plateaued. In 2007, as in previous years, 
the majority of these cases occurred among adults, and injection-drug use was the most common risk factor.
Interpretation: The results documented in this report suggest that implementation of the 1999 recommendations 
for routine childhood hepatitis A vaccination in areas of the United States with consistently elevated hepatitis A rates 
has reduced rates of infection. In addition, universal vaccination of children against hepatitis B beginning in 1991 has 
reduced disease incidence substantially among younger age groups. Higher rates of hepatitis B continue among adults, 
particularly among males aged 30–44 years, reflecting the need to vaccinate adults at risk for HBV infection. The 
decline in hepatitis C incidence after 1992 was attributable primarily to a decrease in incidence among injection-drug 
users. The reasons for this decrease were unknown but probably reflected changes in behavior and practices among 
injection-drug users.
Public Health Actions: The expansion in 2006 of recommendations for routine hepatitis A vaccination to include all 
children in the United States aged 12–23 months is expected to reduce hepatitis A rates further. Ongoing hepatitis B 
vaccination programs ultimately will eliminate domestic HBV transmission, and increased vaccination of adults with 
risk factors will accelerate progress toward elimination. Further prevention of hepatitis B and hepatitis C relies on iden-
tifying and preventing transmission of HBV or HCV in hospital and nonhospital health-care associated settings. In 
addition, prevention of hepatitis C relies on identifying and counseling uninfected persons at risk for hepatitis C (e.g., 
injection-drug users) regarding ways they can protect themselves from infection. Public health management of persons 
with chronic HBV or HCV infection will help to interrupt the transmission to susceptible persons, and their medical 
management will help to reduce the development of the 
sequelae from chronic liver disease.
Corresponding author: Danni Daniels, MS, Division of Viral 
Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and 
TB Prevention, CDC, 1600 Clifton Rd., N.E., MS G-37, Atlanta, 
GA 30333. Telephone: 404-718-8596; Fax: 404-718-8585. E-mail: 
dld4@cdc.gov.
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Introduction
Viral hepatitis is caused by infection with any of at least five 
distinct viruses, of which the three most commonly identified 
in the United States are hepatitis A virus (HAV), hepatitis B 
virus (HBV) and hepatitis C virus (HCV). All three of these 
unrelated viruses can produce an acute illness characterized 
by nausea, malaise, abdominal pain, and jaundice. HBV and 
HCV also can produce a chronic infection that is associated 
with an increased risk for chronic liver disease and hepatocel-
lular carcinoma.
This report describes the burden of acute disease attributed 
to infection with HAV, HBV, and HCV and describes acute 
disease trends in recent years. These data can be used to develop 
and evaluate prevention strategies and to identify persons in 
need of postexposure prophylaxis. The data on acute illness 
presented in this report do not include the burden of disease 
caused by chronic infection with HBV or HCV, both of which 
remain a substantial public health problem.
Hepatitis A Virus
HAV is transmitted through the fecal-oral route, spreading 
primarily through close personal contact. During 1987–1997, 
an average of 28,000 cases of hepatitis A occurred per year in 
the United States (range: 23,112–35,821), making hepatitis 
A one of the country’s most frequently reported notifiable 
diseases. However, effective vaccines to prevent hepatitis A 
virus infection have been available in the United States since 
1995. These vaccines have provided public health authorities 
with the opportunity to reduce disease incidence in the United 
States substantially and potentially to eliminate indigenous 
transmission.
In 1996, CDC’s Advisory Committee on Immunization 
Practices (ACIP) recommended administration of hepatitis A 
vaccine for persons at increased risk, including international 
travelers, men who have sex with men (MSM), injection- and 
noninjection-drug users, and children living in communities 
with high rates of disease (1). In 1999, ACIP also recom-
mended that routine vaccination be implemented for chil-
dren living in 11 states with average hepatitis A rates during 
1987–1997 of >20 cases per 100,000 population and also be 
considered for children in six states with rates of 10–20 cases 
per 100,000 population (2). In 2006, ACIP expanded these 
recommendations to include routine vaccination of children 
in all 50 states (3).
Hepatitis B Virus 
HBV is transmitted by percutaneous or mucosal exposure 
to the blood or body fluids of an infected person, most often 
through injection-drug use (IDU), sexual contact with an 
infected person, or contact from an infected mother to her 
infant during delivery. Transmission of HBV also can occur 
in settings involving nonsexual interpersonal contact for an 
extended period (e.g., among household contacts of a person 
with chronic HBV infection). In 1991, a comprehensive 
strategy was recommended for the elimination of HBV 
transmission in the United States (4,5). The four elements of 
this strategy are 1) universal vaccination of infants beginning 
at birth, 2) prevention of perinatal HBV infection through 
routine screening of all pregnant women for HBV infection 
and the provision of immunoprophylaxis to infants born to 
infected women or to women of unknown infection status, 
3) routine vaccination of previously unvaccinated children 
and adolescents, and 4) vaccination of adults at increased risk 
for infection (including health-care workers, dialysis patients, 
household contacts and sex partners of persons with chronic 
HBV infection, recipients of certain blood products, persons 
with a recent history of multiple sex partners or a sexually 
transmitted disease, MSM, and injection-drug users).
Hepatitis C Virus
HCV is transmitted primarily through percutaneous expo-
sure; however, transmission can occur through unapparent 
percutaneous or mucosal exposures (e.g., persons with evidence 
of high-risk sexual practices). With an estimated 3.2 million 
chronically infected persons nationwide, HCV infection is 
the most common bloodborne infection in the United States 
(6). No vaccine against HCV infection exists. National rec-
ommendations for prevention and control of HCV infection 
(7), issued in 1998, emphasize primary prevention activities to 
reduce the risk for HCV transmission. These activities include 
screening and testing of blood donors, viral inactivation of 
plasma-derived products, risk-reduction counseling and screen-
ing of persons at risk for HCV infection, and routine practice 
of infection control in health-care settings.
Methods
Conditions for Which Surveillance is 
Conducted 
National surveillance is conducted for acute hepatitis A, B, 
and C. The case definitions for these conditions are approved 
by the Council of State and Territorial Epidemiologists 
(CSTE) and are provided (see Case Definitions for Acute 
Viral Hepatitis).
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Data Sources
Cases of acute viral hepatitis are reported to CDC weekly 
by state and territorial health departments to CDC’s National 
Notifiable Diseases Surveillance System (NNDSS). Since 
January 1, 2002, all reports have been submitted electroni-
cally to CDC via the National Electronic Telecommunications 
System for Surveillance (NETSS).
States’ participation in reporting nationally notifiable dis-
eases, including acute viral hepatitis, is voluntary. All states 
collect and report basic information (e.g., event date, source 
of report, and demographic characteristics) regarding cases of 
acute viral hepatitis that are identified in their states. States 
also are asked to report additional information (e.g., laboratory 
test results, clinical information, and exposure history) regard-
ing investigated cases, but completeness of reporting of these 
additional data varies. Information regarding state-specific 
reporting profiles for risk factor information is provided in 
this report (Table 1).
Case Definitions for Acute Viral 
Hepatitis
In 2007, cases were required to meet the clinical defini-
tion for acute hepatitis and virus-specific laboratory criteria 
for diagnosis specified in the following CSTE-approved case 
definitions (available at http://www.cdc.gov/ncphi/disss/nndss/
casedef/case_definitions.htm#h).
Clinical Case Definition
Acute hepatitis was defined as acute illness with 1) discrete 
onset of symptoms (e.g., nausea, anorexia, fever, malaise, or 
abdominal pain) and 2) jaundice or elevated serum aminotrans-
ferase levels. For acute hepatitis C, elevated serum aminotrans-
ferase levels are specified as serum alanine aminotransferase 
levels of >400 IU/L.
Laboratory Criteria for Diagnosis of 
Hepatitis
Because the clinical characteristics are the same for all types 
of acute viral hepatitis, laboratory testing is needed to identify 
the specific viral cause of illness. The laboratory criteria for 
confirming each type of acute viral hepatitis are as follows:
Acute hepatitis A•	
Immunoglobulin M (IgM) antibody to hepatitis A  –
virus (anti-HAV) positive
Acute hepatitis B•	
IgM antibody to hepatitis B core antigen (anti-HBc)  –
positive or hepatitis B surface antigen (HBsAg) posi-
tive, and
IgM anti-HAV negative (if performed) –
Acute hepatitis C•	
IgM anti-HAV negative, and –
IgM anti-HBc negative, and –
One of the following: –
Antibody to hepatitis C virus (anti-HCV) screening- ï
test-positive with a signal to cut-off ratio predictive 
of a true positive for the particular assay as defined 




Hepatitis C virus recombinant immunoblot assay  ï
(HCV RIBA) positive,
OR
Nucleic acid test (NAT) for HCV RNA positive. ï
Case Classification
For this analysis, a confirmed case was one if it met the clinical 
case definition and was laboratory-confirmed. For hepatitis A, 
a case also was considered confirmed that met the clinical case 
definition and was diagnosed in a person who had an epidemio-
logic link to a person who had laboratory-confirmed hepatitis A 
(i.e., household or sexual contact with an infected person during 
the 15–50 days before the onset of symptoms).
Analyses
Incidence Calculations
For this report, crude rates per 100,000 population were 
calculated using Bureau of the Census estimates of the U.S. 
resident population in 2007. The following U.S. geographic 
regions were used: Midwest, Northeast, South, and West.*
Frequency Analysis
For this analysis, the percentage of persons who reported a 
specific risk factor was determined by using the number of cases 
reporting any information, positive or negative, regarding that 
exposure as the denominator. Depending on the type of hepa-
titis, the percentage of case reports that included any risk factor 
information ranged from 48%–50%. Multiple risk factors may 
be reported for a single person. Consequently, the percentages 
of persons with specific risk factors might total >100%.
*Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, 
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: 
Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, 
Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Dela-
ware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, 
Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, 
Virginia, and West Virginia; and West: Alaska, Arizona, California, Colorado, 
Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, 
and Wyoming.
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Estimation Calculation
The estimation procedure for the number of new cases of 
acute hepatitis A begins with the number of acute hepatitis 
A cases reported voluntarily to CDC via CDC’s NNDSS. 
The overall procedure makes two adjustments to the reported 
number of acute hepatitis A cases: one adjustment accounts for 
underreporting of cases to the passive surveillance system, and 
the other adjustment accounts for anicteric infections assumed 
not to have been recognized or reported. The result of these 
adjustments yields the estimated number of new cases of acute 
hepatitis A. The procedure for estimating the number of new 
cases of acute hepatitis B and acute hepatitis C is similar to 




Historically, acute hepatitis A rates have varied cyclically, with 
nationwide increases every 10–15 years. The national rate of 
hepatitis A has declined steadily since the last peak in 1995. 
In 2007, a total of 2,979 acute symptomatic cases of hepatitis 
A were reported; the national incidence (1.0 case per 100,000 
population) was the lowest ever recorded (Figure 1; Tables 2 
and 3). After asymptomatic infection and underreporting 
were taken into account, an estimated 25,000 new infections 
occurred in 2007 (8).
Rates by Region
In addition to temporal variation, historically, hepatitis A 
rates have varied geographically, with higher rates reported in 
the western region of the United States. However, incidence in 
the West declined substantially, most notably after issuance in 
1999 of recommendations for routine childhood vaccination in 
states with consistently elevated rates of hepatitis A (2). Since 
2002, rates in the West have been approximately equal to those 
in other regions of the United States (Figures 2 and 3).
Rates by Age
Incidence of hepatitis A varies by age. Since the last nation-
wide increase in 1995, the rates overall declined among all 
age groups, but the greatest decreases were among children. 
Historically, the highest rates were observed among children 
and young adults; the lowest rates were among persons aged 
>40 years. In 2007, rates were highest for persons aged 25–39 
years (1.3 cases per 100,000 population) (Figure 4). During 
2001–2007, the lowest rates were among children aged <5 
years. However, asymptomatic infection is common among 
young children, and symptomatic cases in children aged <5 
years represent only a limited proportion of infections that 
occur in this age group. 
Rates by Sex
Rates of hepatitis A consistently have been higher among 
males than among females; during 1996–2002, the difference 
in the sex-specific rates increased until nearly two male cases 
were observed for every female case. However, since 2002, 
overall rates have declined more among males than among 
females. In 2007, incidence among males was 1.1 cases per 
100,000 population, compared with 0.9 cases per 100,000 
population among females (Figure 5). The difference in hepa-
titis A rates by sex was highest among persons aged 35–49 
years (Figure 6).
Rates by Race and Ethnicity
Hepatitis A rates have differed historically by race; the high-
est rates occurred among American Indian/Alaska Natives 
(AI/ANs), and the lowest rates among Asians/Pacific Islanders 
(APIs). However, rates among AI/ANs, which were >60 cases 
per 100,000 population before 1996, have decreased dramati-
cally; during 2001–2007, rates among AI/ANs were lower than 
or similar to those for other races. In 2007, the rate for AI/ANs 
was 0.5 cases per 100,000 population. Historically, hepatitis 
A rates also have differed by ethnicity; rates among Hispanics 
were consistently higher compared with non-Hispanics. Rates 
for Hispanics decreased 94%, from the peak of 24.1 cases per 
100,000 population in 1997 to 1.4 cases per 100,000 popula-
tion in 2007, the lowest rate ever recorded, and approached 
the rate for non-Hispanics (Figure 7).
Reported Risk Factors
In 2007, among cases for which information regarding 
exposures during the incubation period was collected, the most 
frequently identified risk factor for hepatitis A was international 
travel (reported by 18% of case patients overall). As in previ-
ous years, the majority of travel-related cases were associated 
with travel to Mexico and Central/South America (85%). As 
HAV transmission in the United States has decreased, cases 
among travelers to countries in which hepatitis is endemic have 
accounted for an increased proportion of all cases. 
Historically, sexual and household contact with another 
person with hepatitis A has been among the most frequently 
identified risks; in 2007, this type of contact accounted 
for 8% of reported cases. In 2007, the proportion of cases 
reported among MSM was 6%, and the proportion of cases 
in persons reporting IDU was 1% (Table 4; Figure 8). Risk 
factor data were not available for 1,486 (50%) of reported 
cases (Table 4).
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Clinical Characteristics
In 2007, the clinical characteristics of reported hepatitis A 
cases were similar to previous years; 73% of infected persons 
had jaundice, 35% were hospitalized for hepatitis A, and 0.8% 
died from hepatitis A. The proportion of persons hospitalized 
increased with age, from 21% among children aged <5 years 
to 53% among persons aged >60 years (Table 5).
Acute Hepatitis B
overall Incidence
In 2007, a total of 4,519 acute, symptomatic cases of hepa-
titis B were reported nationwide. The overall incidence (1.5 
cases per 100,000 population) was the lowest ever recorded 
and represents a decline of 82% from the rate in 1990 (8.5 
cases per 100,000 population) (Tables 2 and 6; Figure 9). 
After asymptomatic infection and underreporting were taken 
into account, an estimated 43,000 new infections occurred 
in 2007 (8).
Rates by Region
In 2007, hepatitis B rates were similar to those in 2006 in 
all U.S. regions (Figures 10 and 11). During 2000–2007, the 
highest rates occurred in the South.
Rates by Age
Within each age group, hepatitis B rates began to plateau in 
2006. However, hepatitis B rates varied by age, with the high-
est rate in 2007 (2.9 cases per 100,000 population) reported 
among persons aged 25–44 years and the lowest (0.02 cases 
per 100,000 population) reported among persons aged <15 
years. The greatest percentage declines have occurred among 
persons aged <15 years (98%; from 1.2 cases per 100,000 
population in 1990 to 0.02 cases per 100,000 population in 
2007)) and those aged 15–24 years (93%; from 13.0 cases 
per 100,000 population in 1990 to 0.9 cases per 100,000 
population in 2007). Although not as large as the declines in 
the younger age groups, substantial decreases occurred among 
older persons; the percentage declines among persons aged 
25–44 years and those aged >45 years were 79% and 62%, 
respectively (Figure 12).
Rates by Sex
As in previous years, in 2007, the rate of acute hepatitis B 
for males (1.9 cases per 100,000 population) was higher than 
that for females (1.2 cases per 100,000 population). During 
1990–2007, the male-to-female ratio of cases remained stable 
(1.5–1.8). In 2007, the rate for males was approximately 1.6 
times higher than that for females (Figure 13). In 2007, this 
difference in hepatitis B rates by sex occurred primarily among 
persons aged >19 years and increased with age (Figure 14).
Rates by Race and Ethnicity
Since 2004, rates of hepatitis B have plateaued among all 
racial/ethnic populations (Figure 15). In 2007, the rate of 
hepatitis B was highest for non-Hispanic blacks (2.3 cases per 
100,000 population). The downward trend in the rate among 
APIs continued, and the rate for this population in 2007 (0.9 
cases per 100,000 population) was similar to that for Hispanics 
and non-Hispanic whites (1.0 case per 100,000 population, 
for both populations).
Reported Risk Factors for Infection
Of persons for whom information regarding exposures dur-
ing the incubation period was available, 38% had multiple sex 
partners, 11% were MSM, and 6% had sexual contact with 
a person known to have hepatitis B. IDU was reported for 
15% of persons. Having had surgery was reported for 12% of 
persons with hepatitis B; the percentage was higher for persons 
aged >45 years (17%). The proportion of persons who reported 
receiving hemodialysis or a blood transfusion (both of which 
historically were major sources of infection) or having had 
occupational exposure to blood was low (0.2%, 0.5%, and 
0.6%, respectively) (Table 7; Figure 16). Risk factor data were 
not available for 2,361 (52%) of reported cases (Table 7).
Clinical Characteristics
In 2007, of persons reported with hepatitis B, 76% had 
jaundice, 40% were hospitalized, and 2% died. The proportion 
of persons hospitalized for hepatitis B was approximately 40% 
among persons in each age group (Table 8).
Acute Hepatitis C
overall Incidence
In 2007, a total of 849 confirmed cases of acute hepatitis 
C were reported; the overall national rate was 0.3 cases per 
100,000 population (Table 2 and 9; Figure 17). Since 2003, 
hepatitis C rates have plateaued. After asymptomatic infection 
and underreporting were taken into account, approximately 
17,000 new HCV infections occurred in 2007 (8).
Rates by Age
Since 2003, hepatitis C rates have plateaued within each 
age group. In 2007, rates increased slightly among persons 
aged 25–39 years (0.5 per 100,000 population) and those 
aged >40 years (0.3 per 100,000 population). Rates declined 
90% (from 5.3 cases per 100,000 population in 1990 to 0.5 
cases per 100,000 population in 2007) among persons aged 
6 MMWR May 22, 2009
25–39 years, the age group that historically had the highest 
rates of disease. Few cases were reported among persons aged 
<15 years (Figure 18).
Rates by Sex
In 2007, as in previous years, the reported rate of hepatitis 
C was higher for males (0.3 cases per 100,000 population) 
than for females (0.3 cases per 100,000 population). However, 
since 2002, this differential in rates has declined (Figure 19). 
In 2007, among persons aged 15–34 years, the male-to-female 
ratio was <1 (0.5 for persons aged 15–19 year, 0.8 for persons 
aged 20–24 years, and 1.0 for persons aged 25–29 years and 
for persons aged 30–34 years) (Figure 20).
Rates by Race and Ethnicity
Since 2004, the incidence of hepatitis C has plateaued among 
all racial/ethnic populations except for AI/ANs, for whom 
rates fluctuated. In 2007, rates were similar across racial/ethnic 
populations other than AI/ANs, for whom the rate was 0.5 
cases per 100,000 population. For non-AI/AN populations, 
rates ranged from 0.02 cases per 100,000 population among 
APIs to 0.3 cases per 100,000 population among non-Hispanic 
whites (Figure 21).
Reported Risk Factors
Of the cases reported in 2007 for which information con-
cerning exposures during the incubation period was available, 
the most common risk factor identified was IDU (48%). 
During 1998–2007, IDU was reported for an average of 44% 
of persons (range: 38%–54%). In 2007, 42% reported hav-
ing multiple sex partners during the incubation period, 10% 
reported having sexual contact with another known HCV-
infected person, and 10% were MSM. Having had surgery was 
reported for 20% of persons with hepatitis C; the percentage 
was higher for persons aged >40 years (32%). A total of 2% 
reported occupational exposure to blood (Table 10; Figure 22). 
Risk factor data were not available for 438 (52%) of reported 
cases (Table 10).
Clinical Characteristics
In 2007, of persons with hepatitis C whose cases were 
reported, 71% had jaundice, 49% were hospitalized, and 0.5% 
died (Table 11). 
Discussion
National surveillance data for acute viral hepatitis provides 
the information needed to develop prevention strategies and 
monitor their effectiveness. Since national surveillance for 
acute viral hepatitis in the United States began in 1966, major 
changes in the epidemiology of these diseases have occurred. 
During 1995–2007, rates for all three types of acute viral 
hepatitis declined. These declines resulted partially from 
implementation of comprehensive prevention strategies for 
each disease, including the introduction of effective vaccines 
against hepatitis A and hepatitis B.
Hepatitis A 
Hepatitis A rates have varied cyclically, with peaks occurring 
approximately every 10–15 years; the most recent peak in mor-
bidity occurred in 1995. The incidence of hepatitis A began to 
decline after the introduction of licensed hepatitis A vaccines 
in the United States in 1995 and the issuance in 1996 of the 
first public health recommendations for the use of vaccine to 
prevent transmission of HAV (1). The greatest declines have 
occurred since 1999, when recommendations were made for 
routine vaccination of children living in states with consistently 
elevated rates of hepatitis A (2). After implementation of the 
recommended vaccination strategy, major changes occurred 
in the geographic distribution of hepatitis A. Relative to their 
prevaccine-era rates, a substantially greater decline occurred 
for the 17 western and midwestern states included in the 1999 
recommendation than for the remainder of the country (9). 
As a result of this decline, hepatitis A rates now are similar 
across all regions.
After the implementation of routine childhood vaccination, 
changes in the age distribution also occurred. During the pre-
vaccine era, the reported incidence of hepatitis A was highest 
among children aged 5–14 years; approximately one third of 
reported cases occurred among children aged <15 years. Since 
implementation of routine childhood vaccination, incidence 
has declined more sharply among the age groups (i.e., 2–18 
years) covered by the recommendations than among older age 
groups. As a result, rates now are similar among all age groups 
(9). In 2007, the highest rates of disease occurred among 
adults, particularly among males aged 20–39 years. The low 
and relatively stable rates among persons aged >40 years reflect 
the higher proportion of persons in this age group who had 
immunity as a result of previous infection. Data from the 
Third National Health and Nutrition Examination Survey 
(NHANES III) conducted during 1988–1994 indicated that 
approximately 30% of the U.S. population had serologic evi-
dence of immunity to HAV, reaching a high of 75% among 
persons aged >70 years (10).
Disparities in rates among racial/ethnic populations also 
decreased after the introduction of hepatitis A vaccine. In 
particular, rates among AI/ANs were five times those of other 
racial/ethnic population during the prevaccine era. Widespread 
use of hepatitis A vaccine in Native American communities 
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began in 1996 (11), and rates in this population now are 
approximately the same or lower than those of other racial/
ethnic populations. Historically, Hispanics had elevated 
hepatitis A rates. Incidence among Hispanics peaked in 1997 
at 24.1 cases per 100,000 population and declined 94% by 
2007 to 1.4 cases per 100,000 population, approaching the 
rate for non-Hispanics. This decline might reflect the early 
impact of the expansion in 2006 of the recommendation for 
routine vaccination to include children aged 12–23 months 
in all 50 states (3).
The observed declines in the incidence of hepatitis A were 
accompanied by shifts in the epidemiologic profile of this dis-
ease. The substantial communitywide outbreaks that occurred 
as a result of person-to-person contact in households and 
extended family settings have become increasingly rare. The 
disappearance of these outbreaks can be attributed to declining 
rates of infection among children who, because they frequently 
have asymptomatic infection, often have played a key role in 
sustaining HAV transmission. As this type of transmission has 
decreased, the proportion of cases among persons in high-risk 
populations (particularly international travelers and MSM) has 
increased. Although the absolute number of cases associated 
with international travel has remained nearly unchanged, the 
proportion of cases attributable to this exposure has increased, 
accounting for 18% of all cases in 2007. Approximately 85% 
of all travel-related cases were associated with travel to Mexico 
and to Central or South America. Hepatitis A transmission 
also can occur among family members of children recently 
adopted from countries in which hepatitis A is endemic. 
Family members who anticipate close personal contact with 
an internationally adopted child from countries in which 
hepatitis A is of intermediate or high endemicity can benefit 
from hepatitis A vaccination.
Outbreaks of hepatitis A among injection-drug users and 
MSM also have continued to occur although hepatitis A 
vaccine has been recommended for these populations since 
1996.
In 2005, the licensing of hepatitis A vaccines was revised to 
allow vaccination of children aged 12–23 months, which has 
made feasible the incorporation of hepatitis A vaccine into 
the schedule of other routinely recommended childhood vac-
cines. In 2006, ACIP recommended that all children in the 
United States aged 12–23 months receive hepatitis A vaccine 
(3). Nationwide hepatitis A vaccination of children is likely to 
result in further narrowing of current demographic disparities 
and in lower overall rates of infection. The 2006 recommen-
dations provide the foundation for eventual consideration of 
elimination of indigenous HAV transmission in the United 
States. Ongoing surveillance for acute hepatitis A provides the 
data needed to measure the progress toward that goal.
Hepatitis B
The decline in hepatitis B incidence began in the mid-1980s 
and has coincided with the stepwise implementation of the 
national vaccination strategy to eliminate HBV transmission. 
The 2007 rate of 1.5 cases per 100,000 population was the 
lowest recorded since surveillance began in 1966 and represents 
an estimated decline of >80% from the rate in 1990, the year 
before the national strategy was implemented. 
The greatest declines have occurred among the cohort of 
children to whom the recommendations for routine infant 
and adolescent vaccination have applied. The incidence 
among children aged <15 years declined 98%, from 1.2 cases 
per 100,000 population in 1990 to 0.02 cases per 100,000 
population in 2007. This decline correlates with high vaccine 
coverage rates among young children, with the most recent 
data indicating that coverage among children aged 19–35 
months was 93% (12).
Although incidence also has declined among persons aged 
25–44 years, rates in this age group, particularly among males, 
still remained substantially higher than in any other age group. 
A high proportion of these cases occurred among persons 
with risk factors for HBV infection (e.g., injection-drug users, 
MSM, and persons with multiple sex partners). In contrast, the 
continued occurrence of cases among injection-drug users and 
persons with sexual risk factors indicates a need to strengthen 
efforts to reach these populations with vaccine. In 2007, in 
collaboration with 54 state and local health agencies, CDC 
launched the Adult Hepatitis B Vaccination Initiative to pro-
vide approximately $20 million for the purchase of hepatitis B 
or hepatitis A/B vaccine (13). The funds supported the admin-
istration of 232,712 doses of hepatitis B containing vaccine 
in 1,793 clinical sites. In the second year of the initiative, 48 
immunization grantees were awarded $16 million.
Since 1990, progress has been made in reducing racial/
ethnic disparities in hepatitis B rates. Before 1990, APIs had 
disproportionately higher rates of hepatitis B. The decrease in 
disparity between APIs and other racial/ethnic populations was 
consistent with observed declines in the seroprevalence of HBV 
infection among high-risk Asian children after the successful 
implementation of routine hepatitis B vaccination (14,15). 
Although rates among non-Hispanic blacks have declined, 
they remain more than twofold higher than those among 
other racial/ethnic populations. Although progress has been 
made in reducing disparities in incidence of new infection, the 
impact of these disparities in the past are reflected in current 
prevalence patterns, with higher prevalences of chronic HBV 
infection among APIs and non-Hispanic blacks than among 
other populations.
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Few cases now occur in certain populations that previously 
were considered to be at high risk (e.g., dialysis patients and 
health-care workers) as a result of continued improvements in 
infection control and ongoing hepatitis B vaccination in these 
groups. A 2003 survey indicated that approximately 75% of 
health-care workers have been vaccinated against hepatitis 
B (16). In 2002, coverage among dialysis patients was 56% 
(17). Persons aged >45 years reported surgery as a potential 
risk more often than those who were younger. This is prob-
ably related to the increased incidence of surgery among older 
persons. Approximately 40% of persons who reported having 
had surgery during the incubation period also reported being 
injection-drug users, having multiple sex partners, or being 
MSM. Transmission associated with transfusions is rare as a 
result of required screening of blood products. Health-care–
related transmission of hepatitis B is documented infrequently 
in the United States but should be considered when cases of 
acute viral hepatitis are identified in persons without tradi-
tional risk factors. The declining incidence of hepatitis B has 
been associated with increasing recognition of sporadic cases 
associated with health care, including nonhospital health-care 
settings such as outpatient clinics and long-term care facili-
ties (18–20). During 1999–2007, a total of 16 outbreaks of 
hepatitis B were detected and investigated in the United States, 
involving 157 known infected persons; in almost all instances, 
these casers could be attributed to sharing glucose-monitoring 
equipment among persons with diabetes residing in nursing or 
assisted care facilities (20). State and local health authorities 
should consider strategies to improve detection of hospital 
and nonhospital health-care–associated cases, such as targeting 
intensive follow-up for persons who typically are at low risk 
for infection (e.g., persons aged >60 years).
To complement surveillance for acute HBV infection, 
surveillance data also are needed to guide and evaluate public 
health interventions for persons with chronic hepatitis B. 
Approximately 800,000–1.4 million U.S. residents are living 
with chronic HBV infection, and hepatitis B is the underlying 
cause of an estimated 3,000 deaths each year in the United 
States. Improving the identification and public health manage-
ment of persons with chronic HBV infection can help prevent 
serious sequelae of chronic liver disease and complement 
immunization strategies to eliminate HBV transmission in the 
United States. CDC recently issued new guidelines for HBsAg 
testing and including new recommendations for public health 
evaluation and management of chronically infected persons 
and their contacts (21). Surveillance data for chronic hepatitis 
B can be brought together with data from HIV surveillance 
and cancer registries to track progress to guide the integration 
of prevention services and health outcomes. Perinatal HBV 
infection, a notifiable disease, has been reported via NETSS 
since 2001. In 2001, a total of 30 cases were reported by seven 
states, and in 2004, a total of 48 cases were reported by 15 
states. In 2007, a total of 83 cases were reported by 22 states. 
Despite the increase in the number of states reporting cases of 
perinatal HBV infection since 2001, not all states have begun 
reporting through this mechanism. The number of reported 
cases is estimated to represent <10% of the true number of 
infections occurring (22).
Hepatitis C
After peaking in the late 1980s, the incidence of hepatitis 
C declined steadily through the 1990s. However, since 2003, 
hepatitis C rates have plateaued, with IDU remaining the most 
commonly identified risk factor for infection. Transmission 
of HCV associated with transfusion, an important risk for 
infection in previous years, has been rare as a result of required 
blood screening.
Health-care–related transmission of hepatitis C is docu-
mented infrequently in the United States but should be 
considered when cases of acute viral hepatitis are identified 
in persons without traditional risk factors for hepatitis C 
(e.g., IDU). Recognition of sporadic cases associated with 
nonhospital health-care settings such as outpatient clinics and 
hemodialysis centers has been increasing (18–20). In 2007, an 
outbreak of HCV infection occurred in an endoscopy clinic in 
Nevada. This outbreak, which was attributed to unsafe injec-
tion practices, resulted in the notification of approximately 
40,000 persons about their potential risk for exposure to HCV 
infection and other bloodborne pathogens; six cases of acute 
hepatitis C were detected (23). A review of other outbreak 
investigations by CDC and state health departments indicated 
that an additional 15 HCV outbreaks associated with receipt 
of care in nonhospital health-care venues had occurred in the 
United States during 1998–2007; 276 infected persons were 
identified, and >18,000 persons had been exposed and required 
notification and screening (20). State and local health authori-
ties should consider strategies to improve detection of hospital 
and nonhospital health-care–related cases, such as targeting 
intensive follow-up for persons who typically are at low risk 
for infection (e.g., persons aged >60 years).
The incidence of acute hepatitis C has declined substantially 
(from 5.2 cases per 100,000 population in 1995 to 0.5 cases 
per 100,000 population in 2007) among persons aged 25–39 
years, the age group that historically had the highest rates of 
infection. In 2007, cases among children continued to be 
rare. Progress has been made in reducing disparities in racial/
ethnic-specific rates; during 2004– 2007, the incidence of 
acute hepatitis C was similar across all racial/ethnic populations 
with the exception of AI/ANs, for whom rates were higher. 
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Close monitoring of the incidence in specific communities 
remains an important tool in the detection of a disparity. 
However, previous racial/ethnic disparities in incidence were 
demonstrated by disparities in prevalence, with a higher rate 
of chronic infection among non-Hispanic blacks than among 
other racial/ethnic populations (6).
Although the number of new cases of acute hepatitis C has 
declined, a substantial burden of disease as a result of chronic 
infection still persisted in 2007. Approximately 3.2 million 
persons in the United States were chronically infected with 
HCV; the peak prevalence occurred among persons aged 40–49 
years, the majority of whom likely became infected in the 1970s 
and 1980s, when incidence was highest (6). Data on both the 
incidence of acute disease and the prevalence of chronic infec-
tion are needed to assess the burden of disease attributable to 
HCV infection in the United States comprehensively. However, 
surveillance for acute hepatitis C remains critical as the best 
means to assess the impact of primary prevention strategies, 
determine where transmission continues to occur, and identify 
and control outbreaks.
Limitations
The analyses summarized in this report were performed 
on the basis of cases of symptomatic, serologically confirmed 
acute viral hepatitis reported to NNDSS. NNDSS is a passive 
surveillance system and subject to at least two limitations. 
First, the cases reported represent only a portion of all infec-
tions. Surveillance for acute disease is not intended to identify 
asymptomatic infections, and certain persons with symptom-
atic illness also are not identified and reported. Studies have 
estimated that for each hepatitis case reported to NNDSS, 
two to five cases that would meet the case definition are not 
reported (24,25). Second, completeness of case reports also can 
vary. However, available evidence suggests that no systematic 
changes have occurred in reporting patterns since 1990 (CDC, 
unpublished data, 2007). The national trends in this report also 
are reflected in CDC’s Sentinel Counties Study of Acute Viral 
Hepatitis, in which the accuracy and completeness of report-
ing were assessed and known to be high (26). Rates based on 
NNDSS data represent a lower estimate of the incidence of 
acute viral hepatitis in the United States because not all cases 
of acute hepatitis are reported. However, because the propor-
tion of cases not reported has not changed systematically over 
time, these estimates accurately reflect changing trends in these 
diseases in the United States.
Conclusion
Surveillance for acute viral hepatitis accomplishes multiple 
key public health objectives. Surveillance detects outbreaks, 
identifies persons in need of postexposure prophylaxis, and 
provides information on trends in the incidence and risks 
for recent infection that is needed to develop and evaluate 
prevention strategies. The minimum data required to conduct 
surveillance for acute viral hepatitis are laboratory confirmation 
of cases to distinguish the types of acute hepatitis and clinical 
information to verify the case definition. The collection of risk 
data provides valuable information for identifying modes of 
hepatitis transmission and for implementing and evaluating 
prevention strategies.
With continuing declines in the incidence of all types of 
acute viral hepatitis, surveillance efforts should be enhanced to 
ensure complete and accurate reporting of all cases so that the 
impact of strategies for preventing or eliminating transmission 
of these diseases can be monitored and evaluated. In addition, 
effective and feasible systems for conducting surveillance for 
chronic hepatitis virus infections are needed to characterize the 
burden of chronic disease that remains in the United States as 
a result of these infections.
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TABLE 2. Reported number and rate* of cases of acute viral hepatitis, by type and year — United States, 1966–2007
Hepatitis A Hepatitis B Hepatitis C/Non-A, non-B
Year No. Rate No. Rate No. Rate
1966 32,859 16.8 1,497 0.8 —† —
1967 38,909 19.7 2,458 1.3 — —
1968 45,893 23.0 4,829 2.5 — —
1969 48,416 24.0 5,909 3.0 — —
1970 56,797 27.9 8,310 4.1 — —
1971 59,606 28.9 9,556 4.7 — —
1972 54,074 26.0 9,402 4.5 — —
1973 50,749 24.2 8,451 4.0 — —
1974 40,358 19.5 10,631 5.2 — —
1975 35,855 16.8 13,121 6.3 — —
1976 33,288 15.5 14,973 7.1 — —
1977 31,153 14.4 16,831 7.8 — —
1978 29,500 13.5 15,016 6.9 — —
1979 30,407 13.8 15,452 7.0 — —
1980 29,087 12.8 19,015 8.4 — —
1981 25,802 11.3 21,152 9.2 — —
1982 23,403 10.1 22,177 9.6 2,629§ 1.1§
1983 21,532 9.2 24,318 10.4 3,470§ 1.5§
1984 22,040 9.3 26,115 11.1 3,871§ 1.6§
1985¶ 23,257 10.0 26,654 11.5 4,192§ 1.8§
1986¶ 23,430 10.0 26,107 11.2 3,634§ 1.6§
1987 25,280 10.4 25,916 10.7 2,999§ 1.2§
1988 28,507 11.6 23,177 9.4 2,619§ 1.1§
1989 35,821 14.4 23,419 9.4 2,529§ 1.0§
1990 31,441 12.6 21,102 8.5 2,553§ 1.0§
1991 24,378 9.7 18,003 7.1 3,582§ 1.4§
1992 23,112 9.1 16,126 6.3 6,010 2.4
1993 24,238 9.4 13,361 5.2 4,786 1.9
1994 26,796 10.3 12,517 4.8 4,470 1.8
1995 31,582 12.0 10,805 4.1 4,576 1.7
1996 31,032 11.7 10,637 4.0 3,716 1.4
1997 30,021 11.2 10,416 3.9 3,816 1.4
1998 23,229 8.6 10,258 3.8 3,518 1.3
1999 17,047 6.3 7,694 2.8 3,111 1.1
2000 13,397 4.8 8,036 2.9 3,197 1.1
2001 10,615 3.7 7,844 2.8 1,640** 0.7**
2002 8,795 3.1 8,064 2.8 1,223†† 0.5††
2003 7,653 2.6 7,526 2.6 891†† 0.3††
2004 5,683 1.9 6,212 2.1 758 0.3
2005 4,488 1.5 5,494 1.8 694 0.2
2006 3,579 1.2 4,713§§ 1.6§§ 802 0.3
2007¶¶ 2,979 1.0 4,519 1.5 849 0.3
SOURCE: National Notifiable Diseases Surveillance System, 1966–2007.
 * Rate per 100,000 population. 
 † Non-A, non-B hepatitis became a reportable disease in 1982.
 § Numbers and rates shown for hepatitis C/Non-A, non-B hepatitis were unreliable, reflecting the erroneous reporting of chronically infected persons as 
acute cases that occurred when testing for antibody to hepatitis C virus (anti-HCV) first became widely available. 
 ¶ Excludes cases from New York City; data not available for 1985–1986. 
 ** Excludes cases from New Jersey and Missouri.
 †† Excludes cases from Missouri.  
 §§ Excludes cases from Arizona.
 ¶¶ Excludes cases from the District of Columbia; data not available for 2007.
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TABLE 3. Incidence* of acute hepatitis A, by state/area and year — United States, 1995–2007
State/Area 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Alabama 2.2 5.1 2.0 1.9 1.4 1.3 1.8 0.9 0.5 0.2 1.0 0.3 0.5
Alaska 8.3 8.9 5.6 2.8 2.4 2.1 2.5 1.9 1.5 0.6 0.6 0.3 0.7
Arizona 31.6 39.9 51.2 39.5 14.6 9.0 7.7 5.6 5.0 4.6 3.3 2.9 2.4
Arkansas 26.7 20.0 8.8 3.2 3.2 5.4 2.7 2.7 1.4 2.2 0.7 1.7 0.5
California 21.4 20.9 19.9 12.8 10.4 8.8 5.4 4.1 3.2 2.5 2.7 2.7 1.6
Colorado 13.6 13.4 10.3 8.7 5.4 5.2 2.0 1.6 1.4 1.1 1.0 0.9 0.5
Connecticut 2.6 4.3 4.6 3.0 3.9 5.2 7.0 2.7 2.6 2.1 1.5 1.3 0.7
Delaware 1.7 2.9 4.2 0.8 0.3 1.9 2.0 1.9 1.1 0.7 0.7 1.5 1.0
District of Columbia 4.7 7.2 6.8 12.7 11.4 7.0 14.0 14.3 7.7 1.3 1.0 1.7 —†
Florida 4.7 5.1 5.5 4.1 5.7 4.1 5.2 6.3 2.3 1.5 1.5 1.2 0.8
Georgia 1.2 5.6 10.2 11.5 6.2 4.6 11.1 6.0 9.1 3.6 1.4 0.6 0.7
Hawaii 14.1 10.1 12.4 4.5 2.0 1.1 1.4 2.0 1.0 2.1 1.9 0.9 0.5
Idaho 30.3 20.8 12.4 19.1 3.8 3.5 4.3 2.3 1.3 1.4 1.4 0.6 0.5
Illinois 5.6 6.4 7.2 6.8 7.0 5.6 3.5 2.1 1.5 1.2 1.0 0.8 0.9
Indiana 3.3 6.3 5.6 2.9 1.8 2.2 1.7 0.8 1.2 1.0 0.4 0.5 0.4
Iowa 3.8 11.7 17.2 14.0 5.6 2.3 1.2 2.2 1.4 1.7 0.7 0.4 1.6
Kansas 6.3 15.1 10.0 4.1 2.5 4.1 6.7 2.6 1.0 0.8 0.6 1.0 0.4
Kentucky 1.1 1.4 2.0 0.8 1.7 1.6 3.6 1.1 0.9 0.7 0.6 0.8 0.5
Louisiana 4.5 6.0 6.1 4.0 4.9 2.4 1.9 2.0 1.1 1.1 1.4 0.9 0.7
Maine 2.4 2.3 5.3 1.6 2.2 1.7 0.9 0.6 1.6 1.3 0.6 0.6 0.4
Maryland 4.4 5.1 3.7 8.1 5.9 4.0 5.5 5.5 3.2 1.9 1.5 1.1 1.3
Massachusetts 2.7 3.8 4.2 2.1 2.3 2.2 5.9 2.2 3.4 10.3 4.5 1.3 1.0
Michigan 3.8 5.2 14.0 21.7 12.7 4.9 3.3 2.2 2.0 1.4 1.0 1.2 1.0
Minnesota 4.3 3.8 5.2 3.1 2.7 3.7 0.9 1.1 1.0 1.1 0.6 0.6 1.8
Mississippi 8.3 8.3 3.5 2.5 4.6 5.0 1.3 2.2 0.6 0.8 0.7 0.3 0.3
Missouri 25.1 26.3 21.3 11.7 13.0 4.6 1.6 1.5 1.0 0.6 0.4 0.8 0.4
Montana 19.9 14.8 8.1 10.9 2.0 0.8 1.8 1.4 0.9 0.8 1.1 1.2 0.9
Nebraska 4.0 9.5 6.8 1.6 3.2 2.2 2.2 1.1 0.8 0.7 0.9 1.0 1.1
Nevada 21.9 28.1 26.1 13.0 8.1 4.5 3.3 2.5 2.3 0.7 0.9 0.4 0.5
New Hampshire 1.1 1.9 3.0 1.6 1.5 1.5 1.4 0.9 1.5 2.1 6.3 1.7 0.9
New Jersey 3.9 4.9 3.9 4.2 1.9 3.4 3.3 2.2 2.4 2.2 1.8 1.3 1.4
New Mexico 48.0 20.8 20.4 8.9 3.2 3.8 2.2 1.7 1.3 1.3 1.5 0.8 0.6
New York 8.4 5.8 7.2 5.3 3.8 4.2 4.1 3.3 3.1 2.4 2.0 1.1 1.2
North Carolina 1.5 2.8 2.8 1.7 2.2 1.9 3.0 2.5 1.5 1.2 1.0 1.2 0.7
North Dakota 3.6 21.8 2.2 0.6 0.5 0.6 0.5 0.6 0.3 0.3 0.3 0.5 0.3
Ohio 15.8 7.0 3.0 3.5 5.8 2.3 2.3 2.6 1.5 0.4 0.4 0.5 0.6
Oklahoma 43.7 78.6 43.6 20.0 15.9 7.9 3.3 1.5 0.8 0.6 0.2 0.3 0.4
Oregon 86.7 27.4 11.6 13.3 7.6 5.0 3.0 1.8 1.7 1.5 1.3 1.2 0.8
Pennsylvania 2.1 4.5 4.2 3.5 3.0 3.6 2.5 2.4 8.2 1.2 0.7 0.5 0.8
Rhode Island 3.5 2.6 13.3 1.8 3.5 3.0 7.1 3.2 1.6 2.2 1.8 1.5 1.3
South Carolina 1.2 1.5 2.9 1.4 1.2 2.4 2.1 1.6 1.3 0.9 0.9 0.6 0.4
South Dakota 13.6 5.9 3.7 5.5 1.4 0.4 0.4 0.4 — 0.5 0.1 1.2 0.8
Tennessee 37.2 14.6 7.8 4.3 2.7 2.7 3.3 2.1 3.5 1.6 2.4 1.2 0.9
Texas 16.1 18.2 23.3 17.9 12.6 9.2 2.6 3.9 2.8 2.8 2.0 1.4 1.1
Utah 35.2 53.1 26.6 9.3 3.0 3.2 2.9 2.4 1.7 1.5 0.8 0.5 0.3
Vermont 1.4 2.0 2.5 2.9 4.0 1.6 2.6 0.6 1.0 1.3 0.8 1.3 1.3
Virginia 3.6 3.3 3.7 3.3 2.7 2.3 2.3 2.2 1.9 1.9 1.2 0.8 1.2
Washington 17.3 18.2 18.1 18.2 8.8 5.0 3.1 2.7 1.2 1.1 0.8 0.8 0.9
West Virginia 1.3 1.0 0.7 0.5 2.6 3.1 1.6 1.3 2.1 0.3 0.2 0.3 0.6
Wisconsin 3.6 3.8 3.6 3.6 1.5 2.0 1.6 3.6 0.8 2.2 0.9 0.8 0.6
Wyoming 23.0 8.5 7.3 7.7 1.9 0.8 1.4 0.6 0.4 1.0 0.2 0.4 0.6
* Per 100,000 population.
† No cases were reported.
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TABLE 5. Clinical characteristics of patients with acute hepatitis A, by age group — United States, 2007*
Characteristic
Age group (yrs)
<5 5–14 15–39 40–59 >60 Total
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Died from hepatitis 0/64 (0) 0/191 (0) 2/603 (0.3) 3/400 (0.8) 7/273 (2.6) 12/1,531 (0.8)
Hospitalized for hepatitis 14/67 (20.9) 43/203 (21.2) 212/639 (33.2) 142/423 (33.6) 160/301 (53.2) 571/1,633 (35.0)
Had jaundice 42/68 (61.8) 167/197 (84.8) 494/617 (80.1) 286/422 (67.8) 159/280 (56.8) 1,148/1,584 (72.5)
* A total of 2,979 persons with acute hepatitis A, including 12 who died, were reported. Percentages were calculated on the basis of the number of case 
reports with data for age group and the outcome of interest (i.e., jaundice, hospitalization, or death).
TABLE 4. Number and percentage* of patients with acute hepatitis A who reported selected epidemiologic characteristics, by 
age group — United States, 2007
Characteristic†
Age group (yrs)
<15 15–39 >40 Total
No. (%) No. (%) No. (%) No. (%)
Cases reported with risk factor data
Sexual or household  contact with 
  hepatitis A patient 40/172 (23.3) 29/465 (6.2) 20/502 (4.0) 89/1,139 (7.8)
International travel§ 66/212 (31.1) 109/528 (20.6) 55/573 (9.6) 230/1,313 (17.5)
Homosexual activity (male)¶ 1/3 (33.3) 3/72 (4.2) 5/78 (6.4) 9/153 (5.9)
Injection-drug use 1/148 (0.7) 6/340 (1.8) 4/400 (1.0) 11/888 (1.2)
Child/employee in day care center 33/219 (15.1) 12/541 (2.2) 6/599 (1.0) 51/1,359 (3.8)
Suspected food- or waterborne outbreak 11/164 (6.7) 35/421 (8.3) 22/462 (4.8) 68/1,047 (6.5)
Contact of day care child/employee 13/196 (6.6) 30/489 (6.1) 13/521 (2.5) 56/1,206 (4.6)
Other contact with hepatitis A patient** 31/172 (18.0) 46/465 (9.9) 26/502 (5.2) 103/1,139 (9.0)
Unknown 98/236 (41.5) 373/591 (63.1) 534/658 (81.2) 1,005/1,485 (67.7)
Cases reported with no risk factor 
  data available 195 682 609 1,486
Total cases reported 431 1,273 1,267 2,971
 * The percentage of cases for which a specific risk factor was reported was calculated on the basis of the total number of cases for which any information 
for that exposure was reported. Percentages might not total 100% because multiple risk factors might have been reported for a single case.
 † Exposures that occurred during the 2–6 weeks before onset of illness.
 § Of persons with hepatitis A whose cases are attributed to travel to a region endemic for hepatitis A, 85% traveled in Mexico or South/Central America, 
6% in Africa, 4% in Asia/South Pacific, and 6% in the Middle East. 
 ¶ Among males, 11% reported homosexual behavior. 
 ** For example, playmate, drug-sharing contact, or care provider.
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TABLE 6. Incidence* of acute hepatitis B, by state/area and year — United States, 1995–2007
State/Area 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Alabama 2.7 1.8 1.9 1.7 2.0 1.6 2.0 2.3 2.1 1.8 2.0 2.1 2.8
Alaska 2.2 2.6 2.5 2.1 2.9 2.1 1.6 1.9 1.2 1.7 1.2 1.2 1.3
Arizona 2.8 5.3 4.4 4.0 2.9 4.2 3.1 4.6 5.1 5.0 6.3 —† 1.3
Arkansas 3.3 3.7 4.2 4.5 3.8 4.1 4.0 4.4 3.3 4.3 2.6 3.1 2.5
California 5.5 5.4 5.1 4.4 3.7 3.2 2.5 1.8 1.9 1.4 1.1 1.2 1.1
Colorado 3.7 3.5 3.8 2.6 2.4 2.5 2.3 1.8 1.8 1.2 1.3 0.7 0.7
Connecticut 2.6 2.5 1.7 1.2 1.2 1.4 1.4 2.0 2.8 3.1 1.4 1.4 1.1
Delaware 1.3 1.2 1.0 0.5 0.1 1.9 3.6 1.7 1.7 6.4 4.4 5.5 1.7
District of Columbia 3.8 5.9 5.7 3.6 4.8 6.1 2.3 3.9 2.3 3.4 2.4 1.5 —
Florida 4.7 4.6 4.4 3.5 3.9 3.8 3.1 3.3 3.7 2.9 2.7 2.3 1.8
Georgia 1.4 0.8 3.0 2.7 3.0 4.3 5.2 5.7 7.7 1.2 2.2 2.2 1.6
Hawaii 2.7 1.2 0.9 1.5 1.3 1.0 1.8 1.0 2.2 0.9 0.8 0.6 1.3
Idaho 8.8 7.4 4.5 4.0 2.3 0.8 0.8 0.5 0.6 1.0 1.0 1.0 1.0
Illinois 2.5 2.8 2.4 1.9 1.7 1.4 1.7 1.5 1.0 0.9 1.2 1.0 1.0
Indiana 4.2 2.5 1.7 2.0 1.3 1.4 1.2 1.4 1.1 1.3 0.9 1.3 1.0
Iowa 1.6 2.6 1.5 1.9 1.5 1.3 0.8 0.7 0.6 0.6 1.1 0.7 0.9
Kansas 2.0 1.2 1.2 1.1 0.6 1.0 0.5 0.9 0.7 0.7 1.2 0.4 0.3
Kentucky 1.8 2.0 1.1 1.2 1.3 2.0 1.6 1.6 2.3 2.1 1.6 1.6 1.8
Louisiana 5.6 4.8 4.8 5.0 3.9 3.5 2.8 3.0 2.6 1.5 1.5 1.5 2.3
Maine 1.0 0.6 0.5 0.4 0.2 0.4 0.5 1.1 0.5 0.9 1.1 2.0 1.4
Maryland 5.2 3.3 3.4 2.8 2.9 2.5 2.6 2.4 2.4 2.8 2.9 2.6 2.0
Massachusetts 1.9 1.8 1.3 1.3 0.7 0.2 0.6 2.6 3.3 3.1 0.8 0.3 0.7
Michigan 4.1 4.3 4.7 4.8 5.2 4.3 6.2 3.3 2.2 2.4 1.7 1.4 1.2
Minnesota 2.0 2.0 1.3 1.5 1.7 1.2 0.9 1.0 1.1 1.3 0.8 0.6 0.5
Mississippi — 9.0 6.6 3.4 4.7 3.9 3.3 3.2 3.9 3.5 1.8 0.4 1.3
Missouri 8.2 6.1 6.7 4.6 4.2 2.7 2.3 2.1 4.3 2.5 1.3 1.1 0.7
Montana 2.8 2.4 1.4 0.9 2.4 0.9 0.3 1.1 1.7 1.5 1.1 0.5 0.1
Nebraska 2.4 2.4 1.6 1.4 1.3 2.6 2.0 1.8 1.8 2.5 1.0 1.1 0.7
Nevada 4.3 6.0 4.8 4.6 3.3 2.7 2.5 3.3 3.9 3.3 2.0 1.7 1.9
New Hampshire 2.0 1.8 1.5 1.8 1.4 1.5 1.3 2.0 1.9 3.3 2.2 0.8 0.4
New Jersey 4.6 3.5 3.1 2.5 1.7 2.1 3.4 4.0 2.1 2.5 2.7 1.9 1.9
New Mexico 19.1 24.4 14.9 17.9 12.4 7.9 7.4 7.9 1.9 1.1 1.0 1.2 0.7
New York 5.2 4.7 4.5 3.8 2.7 3.7 4.3 4.6 1.6 1.3 1.2 1.0 1.1
North Carolina 4.3 4.6 3.6 3.2 2.9 3.2 2.7 2.8 1.9 2.1 1.9 1.8 1.4
North Dakota 0.8 0.3 1.1 0.6 0.3 0.5 0.3 1.3 0.3 0.6 0 0.2 0.3
Ohio 1.0 1.1 0.8 0.7 0.8 0.9 0.8 1.0 1.4 1.0 1.2 1.1 1.1
Oklahoma 5.3 1.7 2.0 5.2 5.5 5.2 3.3 3.2 2.2 2.3 1.7 2.7 4.2
Oregon 4.1 4.0 3.7 6.1 3.5 3.6 4.8 3.6 3.4 3.1 2.6 2.2 1.6
Pennsylvania 2.4 2.4 2.9 3.0 2.4 2.2 2.7 2.8 2.4 2.4 1.7 1.4 1.5
Rhode Island 1.0 1.9 2.2 7.6 4.3 4.4 3.1 3.4 2.0 0.6 0.5 1.0 1.5
South Carolina 1.5 2.7 2.6 1.7 1.6 0.6 1.8 3.3 4.8 3.5 3.1 2.2 1.5
South Dakota 0.3 0.7 0.1 0.5 0.1 0.3 0.1 0.4 0.5 0.1 1.0 0.6 0.9
Tennessee 12.3 9.7 8.4 5.4 3.8 4.2 4.8 2.5 3.9 3.7 2.7 2.6 2.3
Texas 6.5 6.6 6.4 9.9 4.3 5.1 3.3 5.1 4.4 3.1 3.3 3.5 3.1
Utah 3.8 6.4 4.5 3.1 1.8 1.6 1.1 2.3 2.2 2.1 1.6 1.0 0.6
Vermont 1.2 2.4 1.9 1.7 0.8 1.0 0.8 1.1 0.6 1.0 1.0 0.6 0.8
Virginia 1.8 2.4 2.0 1.6 1.5 2.4 3.0 3.1 3.1 4.1 1.9 1.0 1.9
Washington 4.2 2.9 2.1 2.4 1.9 2.2 2.9 1.4 1.5 1.0 1.0 1.2 1.0
West Virginia 2.9 2.0 0.9 0.8 1.6 1.7 1.9 1.4 2.4 2.9 3.8 4.1 4.5
Wisconsin 1.6 1.7 10.9 9.8 0.6 0.8 0.9 0.9 0.9 0.7 0.9 0.6 0.4
Wyoming 6.9 9.4 5.2 2.3 2.9 0.6 0.6 3.4 6.2 1.8 0.6 0.2 1.0
* Per 100,000 population.
† No cases were reported.
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TABLE 8. Clinical characteristics of patients with acute hepatitis B, by age group — United States, 2007*
Age group (yrs)
Characteristic
<15 15–39 40–59 >60 Total
No. (%) No. (%) No. (%) No. (%) No. (%)
Died from hepatitis 0/2 (0) 10/1,181 (0.8) 18/1,093 (1.6) 10/226 (4.4) 38/2,502 (1.5)
Hospitalized for hepatitis 2/5 (40.0) 515/1,271 (40.5) 472/1,163 (40.6) 86/224 (38.4) 1,075/2,663 (40.4)
Had jaundice 1/3 (33.3) 981/1,228 (79.9) 778/1,059 (73.5) 136/205 (66.3) 1,896/2,495 (76.0)
* A total of 4,519 persons with acute hepatitis B, including 38 who died, were reported. Percentages were calculated on the basis of the number of case 
reports with data for age group and the outcome of interest (i.e., jaundice, hospitalization, or death).
TABLE 7. Number and percentage* of patients with acute hepatitis B who reported selected epidemiologic characteristics, by age 




No. (%) No. (%) No. (%)
Cases reported with risk factor data
Injection-drug use 229/1,200 (19.1) 55/688 (8.0) 284/1,888 (15.0)
Sexual contact with hepatitis B patient 62/851 (7.3) 22/505 (4.4) 84/1,356 (6.2)
Household contact of hepatitis B patient 19/851 (2.2) 12/505 (2.4) 31/1,356 (2.3)
Homosexual activity (male)§ 46/400 (11.5) 16/189 (8.5) 62/589 (10.5)
Medical employee with blood contact 5/1,236 (0.4) 6/719 (0.8) 11/1,955 (0.6)
Hemodialysis 1/1,032 (0.1) 2/589 (0.3) 3/1,621 (0.2)
Had>1 sex partner 322/744 (43.3) 118/405 (29.1) 440/1,149 (38.3)
   Heterosexual 293/708 (41.4) 110/390 (28.2) 403/1,098 (36.7)
   Homosexual or bisexual (male) 29/36 (80.6) 8/15 (53.3) 37/51 (72.5)
Blood transfusion 1/1,221 (0.1) 8/709 (1.1) 9/1,930 (0.5)
Surgery 102/1,165 (8.8) 112/671 (16.7) 214/1,836 (11.7)
Percutaneous injury (e.g., needlestick) 52/1,080 (4.8) 21/631 (3.3) 73/1,711 (4.3)
Unknown 757/1,363 (55.5) 483/775 (62.3) 1,240/2,138 (58.0)
Cases reported with no risk factor data available 1,468 893 2,361
Total cases reported 2,831 1,668 4,499
* The percentage of cases for which a specific risk factor was reported was calculated on the basis of the total number of cases for which any information 
for that exposure was reported. Percentages might not total 100% because multiple risk factors might have been reported for a single case.
† Exposures that occurred during the 6 weeks–6 months before onset of illness.
§ Among males, 18% reported homosexual behavior.
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TABLE 9. Incidence* of acute hepatitis C, by state/area and year — United States, 1995–2007
State/Area 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Alabama 0.1 0.2 0.3 0.1 0 0.2 0.1 0.2 0.1 0.1 0.3 0.2 0.2
Alaska 0.5 0.5 —† — — — — — — — — — 0.1
Arizona 1.4 1.7 0.6 0.4 1.0 0.4 0.2 0.1 0.1 0 — — —
Arkansas 0.3 0.3 0.6 1.2 1.2 0.4 0.6 0.4 0.1 0.1 0 0 —
California 1.6 1.5 2.7 2.6 0.6 0.3 0.3 0.2 0.1 0.1 0.1 0.1 0.2
Colorado 1.8 1.7 1.0 0.8 0.9 0.4 0.2 0.1 0.3 0.3 0.5 0.6 0.4
Connecticut — — — — — — — — — 0.1 0.3 0.4 0.6
Delaware — 0.1 — — — 0.3 1.4 — — 5.4 — 0.4 —
District of Columbia — — — — 0.2 0.5 — — — 0.7 0 0.3 —
Florida 0.9 0.9 1.0 0.7 0.5 0.3 0.4 0.5 0.4 0.2 0.1 0.3 0.1
Georgia 0.4 — — 0.1 0.1 0 — 0.7 0.1 0.2 0.1 0.1 0.2
Hawaii 10.5 18.3 15.3 4.5 — 0.2 — 0.1 0.3 0.2 0.1 0.5 —
Idaho 5.0 8.3 7.1 7.1 0.6 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.3
Illinois 0.7 0.8 0.7 0.3 0.4 0.2 0.1 0.2 0.2 0.1 0 0.1 0.1
Indiana 0.2 0.1 0.2 0.1 0.1  — 0 0 0.2 0.2 0.4 0 0.2
Iowa 0.5 1.9 1.0 0.3 — 0.1 — 0 0 — — — —
Kansas 0.7 0.6 0.5 0.2 — 0.3 0.3 — — — — — —
Kentucky 0.9 0.7 0.4 0.6 0.7 1.0 0.3 0.1 0.6 0.7 0.4 0.9 0.7
Louisiana 5.1 6.7 6.3 3.1 6.9 10.2 3.4 2.2 2.3 0.1 0 0.2 0.1
Maine — — — — 0.2 0.2 0.1 — 0.2 — — 0.2 0.1
Maryland 0.1 0.1 0.2 0.4 0.4 0.3 0.2 0.3 0.2 0.3 0.1 0.3 0.3
Massachusetts 1.7 1.2 0.8 0.8 0.1 0.3 0.4 0.1 — 0.1 — — 0.2
Michigan 2.5 3.6 4.0 4.8 8.3 2.0 1.4 0.9 1.0 0.8 1.0 1.0 0.9
Minnesota 0.1 0.2 0.1 0.4 0.5 0.3 0.7 0.3 0.5 0.4 0.3 0.2 0.5
Mississippi — 5.6 4.1 3.0 7.1 10.7 3.8 3.2 1.5 1.0 0.6 0.1 0.5
Missouri 0.4 0.4 0.2 0.3 5.8 10.8 19.8 10.8 4.5 0.1 0.2 0.5 0.1
Montana 2.1 2.3 2.7 0.9 0.6 0.6 0.1 0.1 0.4 0.2 0.1 — 0.1
Nebraska 1.4 0.5 0.2 0.3 0.2 0.3 0.6 0.9 0.2 0.1 0.2 — 0.1
Nevada 1.7 1.3 1.1 1.1 0.6 0.9 0.6 1.4 1.2 0.7 0.4 0.3 0.4
New Hampshire 1.2 0.6 — — — — — — — — — — —
New Jersey 2.4 — — — — 6.7 14.3 0.1 — — 0.2 1.0 1.1
New Mexico 3.2 4.5 3.5 5.6 2.0 0.9 0.7 0.2 — 0.4 0.1 0.2 0.3
New York 1.9 1.5 1.5 0.7 0.4 0.2 0.2 0.3 0.1 0.1 0.1 0.2 0.2
North Carolina 0.9 0.6 0.7 0.3 0.4 0.2 0.3 0.3 0.2 0.1 0.2 0.2 0.2
North Dakota 1.1 — 0.6 — 0.2 0.2 — — — 0.8 0.2 — —
Ohio 0.1 0.3 0.2 0.1 0 0.1 0.1 0 0.1 0.1 0.1 0.1 0.2
Oklahoma 1.7 0.2 0.3 0.7 0.5 0.5 0.2 0.6 0.2 0.2 0.4 0.5 1.4
Oregon 1.2 0.3 0.1 0.6 0.7 0.8 0.4 0.4 0.4 0.3 0.4 0.3 0.4
Pennsylvania 0.5 0.5 0.7 1.0 0.6 0.4 1.2 0.5 0.9 0.5 0.5 0.4 0.3
Rhode Island 0.8 0.6 0.8 0.4 0.3 0.7 — 0.1 0.1 — — 0.1 0.8
South Carolina 0.6 0.9 1.1 0.5 0.6 0.1 0.3 0.1 0.6 0.1 0 — —
South Dakota 0.1 — — — — — — 0.1 — — — — —
Tennessee 18.8 7.5 4.5 3.2 2.2 2.0 1.2 0.5 0.4 0.6 0.5 0.5 0.6
Texas 1.9 1.1 2.0 2.3 1.8 1.3 2.3 1.3 0.2 0.5 0.5 0.2 0.3
Utah 0.7 0.9 0.2 1.0 0.3 0.6 0.1 0.2 — 0.3 0.2 0.4 0.2
Vermont 2.4 4.4 0.7 1.0 1.2 0.8 1.1 2.4 2.1 1.3 2.7 3.7 1.4
Virginia 0.3 0.3 0.4 0.2 0.2 0 0 0.2 0.2 0.2 0.2 0.1 0.1
Washington 4.3 1.2 0.7 0.5 0.4 0.7 0.5 0.4 0.3 0.4 0.3 0.4 0.3
West Virginia 2.4 0.5 1.0 0.5 1.2 1.3 1.4 0.2 1.1 1.3 1.0 1.3 1.0
Wisconsin — — 0.5 2.8 0.3 — — 0.1 0.1 — — 0 0
Wyoming 46.6 37.3 17.3 21.2 18.3 0.4 1.6 1.0 — 0.4 — — —
* Per 100,000 population.
† No cases were reported.
Vol. 58 / SS-3 Surveillance Summaries 17
TABLE 11. Clinical characteristics of patients with acute hepatitis C, by age group — United States, 2007*
Age group (yrs)
Characteristic
<5 5–14 15–39 40–59 >60 Total
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Died from hepatitis 0/1 (0) 0/0 (0) 0/248 (0) 0/146 (0) 2/25 (8.0) 2/420 (0.5)
Hospitalized for hepatitis 1/1 (100.0) 0/0 (0) 136/291 (46.7) 89/175 (50.9) 16/27 (59.3) 242/494 (49.0)
Had jaundice 1/1 (100.0) 0/0 (0) 202/287 (70.4) 118/165 (71.5) 19/25 (76.0) 340/478 (71.1)
* A total of 849 persons with acute hepatitis C were reported. Percentages were calculated on the basis of the number of case reports with data for age 
group and the outcome of interest (i.e., jaundice, hospitalization, or death).
TABLE 10. Number and percentage* of patients with acute hepatitis C who reported selected epidemiologic characteristics, by 




No. (%) No. (%) No. (%)
Cases reported with risk factor data
Injection-drug use 130/217 (59.9) 38/135 (28.1) 168/352 (47.7)
Sexual contact with hepatitis C patient 8/51 (15.7) 1/39 (2.6) 9/90 (10.0)
Household contact of hepatitis C patient 2/51 (3.9) 3/39 (7.7) 5/90 (5.6)
Homosexual activity (male)¶ 5/33 (15.2) 1/25 (4.0) 6/58 (10.3)
Medical employee with blood contact 2/215 (0.9) 6/143 (4.2) 8/358 (2.2)
Hemodialysis 0/200 (0) 2/136 (1.5) 2/336 (0.6)
>1 sex partner 67/140 (47.9) 30/91 (33.0) 97/231 (42.0)
Blood transfusion 0/204 (0) 0/135 (0) 0/339 (0)
Surgery 23/181 (12.7) 39/123 (31.7) 62/304 (20.4)
Percutaneous injury (e.g., needlestick) 15/164 (9.1) 6/111 (5.4) 21/275 (7.6)
Unknown 71/243 (29.2) 71/163 (43.6) 142/406 (35.0)
Cases with no reported risk factor data available 221 217 438
Total cases reported 464 380 844
* The percentage of cases for which a specific risk factor was reported was calculated on the basis of the total number of cases for which any information 
for that exposure was reported. Percentages might not total 100% because multiple risk factors might have been reported for a single case.
† Exposures that occurred during the 6 weeks–6 months before onset of illness.
§ A total of 34 (4%) patients were aged <19 years.
¶ Among males, 19% reported homosexual behavior.
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FIGURE 1. Incidence* of acute hepatitis A, by year — United 
States, 1982–2007
FIGURE 2. Incidence* of acute hepatitis A, by region† and 
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* Per 100,000 population.
* Per 100,000 population.
† Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, 
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: 
Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, 
New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, 
Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, 
Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South 
Carolina, Tennessee, Texas, Virginia, and West Virginia; and West: Alaska, 
Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New 
Mexico, Oregon, Utah, Washington, and Wyoming.
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FIGURE 3. Incidence* of acute hepatitis A, by county — United States, 2007
SOURCE: National Notifiable Diseases Surveillance System, 2007.
* Per 100,000 population.
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* Per 100,000 population.
* Per 100,000 population.
* Per 100,000 population.
† The bars indicate the rate per 100,000 (left y-axis) by sex; the line is the 
ratio (right y-axis) of the incidence rate among males compared with that 
among females.
* Per 100,000 population.
† A total of 2,979 cases of acute hepatitis A were reported. Rates exclude 























































































































































FIGURE 4. Incidence* of acute hepatitis A, by age group and 
year — United States, 1990–2007
FIGURE 7. Incidence* of acute hepatitis A, by race/ethnicity 
and year — United States, 1990–2007
FIGURE 5. Incidence* of acute hepatitis A, by sex and year — 
United States, 1990–2007
FIGURE 6. Incidence* of acute hepatitis A, by age group and 
sex — United States, 2007†
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* The percentage of cases among persons in which a specific risk factor was reported was calculated based on the total number of persons for whom any 
information for that exposure was reported. Multiple risk factors may be reported for a single case. 
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FIGURE 10. Incidence* of acute hepatitis B, by region† and 



















* Per 100,000 population.
† Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, 
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: 
Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, 
New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, 
Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, 
Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South 
Carolina, Tennessee, Texas, Virginia, and West Virginia; and West: Alaska, 
Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New 
Mexico, Oregon, Utah, Washington, and Wyoming.
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FIGURE 11. Incidence* of acute hepatitis B, by county — United States, 2007
SOURCE: National Notifiable Diseases Surveillance System, 2007.
* Per 100,000 population.
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FIGURE 12. Incidence* of acute hepatitis B, by age group and 
year — United States, 1990–2007
* Per 100,000 population.
† The bars indicate the rate per 100,000 (left y-axis) by sex; the line is the 















































FIGURE 13. Incidence* of acute hepatitis B, by sex and year — 
United States, 1990–2007
* Per 100,000 population.
† A total of 4,519 cases of acute hepatitis B were reported. Rates exclude 


















































FIGURE 14. Incidence* of acute hepatitis B, by age group and 
sex — United States, 2007†






















FIGURE 15. Incidence* of acute hepatitis B, by race/ethnicity 
and year — United States, 1990–2007
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* The percentage of cases among persons in which a specific risk factor was reported was calculated based on the total number of persons for whom any 
information for that exposure was reported. Multiple risk factors may be reported for a single case. 

















































































































Multiple sex partners Blood transfusion Medical employee with blood contact
26 MMWR May 22, 2009















* Per 100,000 population.
† Until 1995, acute hepatitis C was reported as acute hepatitis non-A, non-B.
* Per 100,000 population.





















FIGURE 18. Incidence* of acute hepatitis C, by age group and 
year — United States, 1992–2007†
* Per 100,000 population.
† Until 1995, acute hepatitis C was reported as acute hepatitis non-A, non-B.
§ The bars indicate the rate per 100,000 (left y-axis) by sex; the line is the 































FIGURE 19. Incidence* of acute hepatitis C, by sex and year — 
United States, 1992–2007†
* Per 100,000 population.
† A total of 849 cases of acute hepatitis C were reported. Rates exclude 















































FIGURE 20. Incidence* of acute hepatitis C, by age group and 
sex — United States, 2007†
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* Per 100,000 population.


















FIGURE 21. Incidence* of acute hepatitis C, by race/ethnicity 
and year — United States, 1992–2007†
* The percentage of cases among persons in which a specific risk factor was reported was calculated based on the total number of persons for whom any 
information for that exposure was reported. Multiple risk factors may be reported for a single case. 
FIGURE 22. Trends in selected epidemiologic characteristics among patients with acute hepatitis C, by year — United States, 
2001–2007*
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